Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

By  

Nephron, Vol. 134, Iss. 4, 2016-07 ,pp. : 215-220

Karger

Access to resources Recommend Favorite

Responses to Diuretic Treatment in Gene-Targeted Mice Lacking Serum- and Glucocorticoid-Inducible Kinase 1

By  

Kidney and Blood Pressure Research, Vol. 32, Iss. 2, 2009-04 ,pp. : 119-127

Karger

Access to resources Recommend Favorite

Impact of Annexin A 7 Deficiency on FGF23 Plasma Concentrations

By  

Kidney and Blood Pressure Research, Vol. 41, Iss. 6, 2016-11 ,pp. : 828-836

Karger

Access to resources Recommend Favorite

Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency

By  

Nephron, Vol. 131, Iss. 3, 2015-0 ,pp. : 161-166

Karger

Access to resources Recommend Favorite

FGF23: A Mature Renal and Cardiovascular Risk Factor?

By  

Blood Purification, Vol. 36, Iss. 1, 2013-05 ,pp. : 52-57

Karger

Access to resources Recommend Favorite